Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently weighed in on the stock. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research note on Monday, March 10th. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tenax Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $6.41 on Thursday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The company’s fifty day moving average is $6.44 and its 200 day moving average is $5.25.

Institutional Trading of Tenax Therapeutics

A number of institutional investors have recently bought and sold shares of TENX. Stonepine Capital Management LLC bought a new stake in Tenax Therapeutics during the third quarter valued at $173,000. Vestal Point Capital LP bought a new stake in Tenax Therapeutics during the third quarter valued at $288,000. Sphera Funds Management LTD. bought a new stake in Tenax Therapeutics during the third quarter valued at $101,000. Geode Capital Management LLC boosted its position in Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Tenax Therapeutics during the fourth quarter valued at about $1,026,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.